Clinical trial

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

NCT07703722

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Psilocybin Find medicine records · Find other trials using this name

BEHAVIORAL · Unmapped registry intervention Structured Integrated Reframing Therapy (SIRT) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Selective Serotonin Reuptake Inhibitor (SSRI) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-04-01

PhasePHASE3

Conditions

Major Depressive Disorderverified · MONDO: major depressive disorder

Post-Traumatic Stress Disorder (PTSD)unresolved

Interventions

PsilocybinDRUG

Structured Integrated Reframing Therapy (SIRT)BEHAVIORAL

Selective Serotonin Reuptake Inhibitor (SSRI)DRUG

Sponsors & collaborators

Khyber Medical University Peshawarlead sponsor

Hayatabad Medical Complexcollaborator

KMU Institute of Health Science, Islamabadcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07703722 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.